Bill Text: MN SF1335 | 2013-2014 | 88th Legislature | Introduced
Bill Title: Schedule I controlled substance schedule additions
Spectrum: Bipartisan Bill
Status: (Introduced - Dead) 2013-03-13 - Referred to Judiciary [SF1335 Detail]
Download: Minnesota-2013-SF1335-Introduced.html
1.2relating to public safety; adding to the list of Schedule I controlled substances;
1.3amending Minnesota Statutes 2012, section 152.02, subdivision 2.
1.4BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.5 Section 1. Minnesota Statutes 2012, section 152.02, subdivision 2, is amended to read:
1.6 Subd. 2. Schedule I. (a) Schedule I consists of the substances listed in this
1.7subdivision.
1.8(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of
1.9the following substances, including their analogs, isomers, esters, ethers, salts, and salts
1.10of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
1.11ethers, and salts is possible:
1.12(1) acetylmethadol;
1.13(2) allylprodine;
1.14(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
1.15levomethadyl acetate);
1.16(4) alphameprodine;
1.17(5) alphamethadol;
1.18(6) alpha-methylfentanyl benzethidine;
1.19(7) betacetylmethadol;
1.20(8) betameprodine;
1.21(9) betamethadol;
1.22(10) betaprodine;
1.23(11) clonitazene;
1.24(12) dextromoramide;
2.1(13) diampromide;
2.2(14) diethyliambutene;
2.3(15) difenoxin;
2.4(16) dimenoxadol;
2.5(17) dimepheptanol;
2.6(18) dimethyliambutene;
2.7(19) dioxaphetyl butyrate;
2.8(20) dipipanone;
2.9(21) ethylmethylthiambutene;
2.10(22) etonitazene;
2.11(23) etoxeridine;
2.12(24) furethidine;
2.13(25) hydroxypethidine;
2.14(26) ketobemidone;
2.15(27) levomoramide;
2.16(28) levophenacylmorphan;
2.17(29) 3-methylfentanyl;
2.18(30) acetyl-alpha-methylfentanyl;
2.19(31) alpha-methylthiofentanyl;
2.20(32) benzylfentanyl beta-hydroxyfentanyl;
2.21(33) beta-hydroxy-3-methylfentanyl;
2.22(34) 3-methylthiofentanyl;
2.23(35) thenylfentanyl;
2.24(36) thiofentanyl;
2.25(37) para-fluorofentanyl;
2.26(38) morpheridine;
2.27(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
2.28(40) noracymethadol;
2.29(41) norlevorphanol;
2.30(42) normethadone;
2.31(43) norpipanone;
2.32(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
2.33(45) phenadoxone;
2.34(46) phenampromide;
2.35(47) phenomorphan;
2.36(48) phenoperidine;
3.1(49) piritramide;
3.2(50) proheptazine;
3.3(51) properidine;
3.4(52) propiram;
3.5(53) racemoramide;
3.6(54) tilidine;
3.7(55) trimeperidine.
3.8(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
3.9and salts of isomers, unless specifically excepted or unless listed in another schedule,
3.10whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
3.11(1) acetorphine;
3.12(2) acetyldihydrocodeine;
3.13(3) benzylmorphine;
3.14(4) codeine methylbromide;
3.15(5) codeine-n-oxide;
3.16(6) cyprenorphine;
3.17(7) desomorphine;
3.18(8) dihydromorphine;
3.19(9) drotebanol;
3.20(10) etorphine;
3.21(11) heroin;
3.22(12) hydromorphinol;
3.23(13) methyldesorphine;
3.24(14) methyldihydromorphine;
3.25(15) morphine methylbromide;
3.26(16) morphine methylsulfonate;
3.27(17) morphine-n-oxide;
3.28(18) myrophine;
3.29(19) nicocodeine;
3.30(20) nicomorphine;
3.31(21) normorphine;
3.32(22) pholcodine;
3.33(23) thebacon.
3.34(d) Hallucinogens. Any material, compound, mixture or preparation which contains
3.35any quantity of the following substances, their analogs, salts, isomers (whether optical,
3.36positional, or geometric), and salts of isomers, unless specifically excepted or unless listed
4.1in another schedule, whenever the existence of the analogs, salts, isomers, and salts of
4.2isomers is possible:
4.3(1) methylenedioxy amphetamine;
4.4(2) methylenedioxymethamphetamine;
4.5(3) methylenedioxy-N-ethylamphetamine (MDEA);
4.6(4) n-hydroxy-methylenedioxyamphetamine;
4.7(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
4.8(6) 2,5-dimethoxyamphetamine (2,5-DMA);
4.9(7) 4-methoxyamphetamine;
4.10(8) 5-methoxy-3, 4-methylenedioxy amphetamine;
4.11(9) alpha-ethyltryptamine;
4.12(10) bufotenine;
4.13(11) diethyltryptamine;
4.14(12) dimethyltryptamine;
4.15(13) 3,4,5-trimethoxy amphetamine;
4.16(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
4.17(15) ibogaine;
4.18(16) lysergic acid diethylamide (LSD);
4.19(17) mescaline;
4.20(18) parahexyl;
4.21(19) N-ethyl-3-piperidyl benzilate;
4.22(20) N-methyl-3-piperidyl benzilate;
4.23(21) psilocybin;
4.24(22) psilocyn;
4.25(23) tenocyclidine (TPCP or TCP);
4.26(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
4.27(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
4.28(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
4.29(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
4.30(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
4.31(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
4.32(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
4.33(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
4.34(32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD);
4.35(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
4.36(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
5.1(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
5.2(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
5.3(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
5.4(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
5.5(2-CB-FLY);
5.6(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
5.7(40) alpha-methyltryptamine (AMT);
5.8(41) N,N-diisopropyltryptamine (DiPT);
5.9(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
5.10(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
5.11(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
5.12(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
5.13(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
5.14(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
5.15(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
5.16(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
5.17(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
5.18(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
5.19(52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
5.20(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
5.21(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
5.22(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
5.23(56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);
5.24(57) methoxetamine (MXE);
5.25(58) 5-iodo-2-aminoindane (5-IAI);
5.26(59) 5,6-methylenedioxy-2-aminoindane (MDAI).;
5.27(60) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
5.28(25I-NBOMe).
5.29(e) Peyote. All parts of the plant presently classified botanically as Lophophora
5.30williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part
5.31of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation
5.32of the plant, its seeds or extracts. The listing of peyote as a controlled substance in
5.33Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies
5.34of the American Indian Church, and members of the American Indian Church are exempt
5.35from registration. Any person who manufactures peyote for or distributes peyote to the
6.1American Indian Church, however, is required to obtain federal registration annually and
6.2to comply with all other requirements of law.
6.3(f) Central nervous system depressants. Unless specifically excepted or unless listed
6.4in another schedule, any material compound, mixture, or preparation which contains any
6.5quantity of the following substances, their analogs, salts, isomers, and salts of isomers
6.6whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
6.7(1) mecloqualone;
6.8(2) methaqualone;
6.9(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
6.10(4) flunitrazepam.
6.11(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
6.12material compound, mixture, or preparation which contains any quantity of the following
6.13substances, their analogs, salts, isomers, and salts of isomers whenever the existence of
6.14the analogs, salts, isomers, and salts of isomers is possible:
6.15 (1) aminorex;
6.16(2) cathinone;
6.17(3) fenethylline;
6.18 (4) methcathinone;
6.19(5) methylaminorex;
6.20(6) N,N-dimethylamphetamine;
6.21(7) N-benzylpiperazine (BZP);
6.22(8) methylmethcathinone (mephedrone);
6.23(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
6.24(10) methoxymethcathinone (methedrone);
6.25(11) methylenedioxypyrovalerone (MDPV);
6.26(12) fluoromethcathinone;
6.27(13) methylethcathinone (MEC);
6.28(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
6.29(15) dimethylmethcathinone (DMMC);
6.30(16) fluoroamphetamine;
6.31(17) fluoromethamphetamine;
6.32(18) α-methylaminobutyrophenone (MABP or buphedrone);
6.33(19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);
6.34(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
6.35(21) naphthylpyrovalerone (naphyrone); and
7.1(22) any other substance, except bupropion or compounds listed under a different
7.2schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
7.31-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
7.4compound is further modified in any of the following ways:
7.5(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
7.6haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
7.7system by one or more other univalent substituents;
7.8(ii) by substitution at the 3-position with an acyclic alkyl substituent;
7.9(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
7.10methoxybenzyl groups; or
7.11(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
7.12(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
7.13specifically excepted or unless listed in another schedule, any natural or synthetic material,
7.14compound, mixture, or preparation that contains any quantity of the following substances,
7.15their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
7.16whenever the existence of the isomers, esters, ethers, or salts is possible:
7.17(1) marijuana;
7.18(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
7.19synthetic equivalents of the substances contained in the cannabis plant or in the
7.20resinous extractives of the plant, or synthetic substances with similar chemical structure
7.21and pharmacological activity to those substances contained in the plant or resinous
7.22extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
7.23tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
7.24(3) synthetic cannabinoids, including the following substances:
7.25(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
7.26structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
7.27alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
7.282-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
7.29extent and whether or not substituted in the naphthyl ring to any extent. Examples of
7.30naphthoylindoles include, but are not limited to:
7.31(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
7.32(B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);
7.33(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
7.34(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
7.35(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
7.36(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
8.1(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
8.2(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
8.3(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
8.4(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
8.5(ii) Napthylmethylindoles, which are any compounds containing a
8.61H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
8.7of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8.81-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
8.9substituted in the indole ring to any extent and whether or not substituted in the naphthyl
8.10ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
8.11(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
8.12(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).
8.13(iii) Naphthoylpyrroles, which are any compounds containing a
8.143-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
8.15pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8.161-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
8.17further substituted in the pyrrole ring to any extent, whether or not substituted in the
8.18naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
8.19(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
8.20(iv) Naphthylmethylindenes, which are any compounds containing a
8.21naphthylideneindene structure with substitution at the 3-position of the indene
8.22ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8.231-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
8.24substituted in the indene ring to any extent, whether or not substituted in the naphthyl
8.25ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
8.26E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
8.27(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
8.28structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
8.29alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
8.302-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
8.31any extent, whether or not substituted in the phenyl ring to any extent. Examples of
8.32phenylacetylindoles include, but are not limited to:
8.33(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
8.34(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
8.35(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
8.36(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
9.1(vi) Cyclohexylphenols, which are compounds containing a
9.22-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
9.3of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.41-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
9.5substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
9.6but are not limited to:
9.7(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
9.8(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
9.9(Cannabicyclohexanol or CP 47,497 C8 homologue);
9.10(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
9.11-phenol (CP 55,940).
9.12(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
9.13structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
9.14alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
9.152-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
9.16any extent and whether or not substituted in the phenyl ring to any extent. Examples of
9.17benzoylindoles include, but are not limited to:
9.18(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
9.19(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
9.20(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
9.21(WIN 48,098 or Pravadoline).
9.22(viii) Others specifically named:
9.23(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
9.24-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
9.25(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
9.26-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
9.27(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
9.28-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2).;
9.29(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
9.30(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
9.31(XLR-11);
9.32(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
9.33(AKB-48(APINACA));
9.34(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
9.35(5-Fluoro-AKB-48);
9.36(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22); and
10.1(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
10.2PB-22).
10.3(i) A controlled substance analog, to the extent that it is implicitly or explicitly
10.4intended for human consumption.
1.3amending Minnesota Statutes 2012, section 152.02, subdivision 2.
1.4BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:
1.5 Section 1. Minnesota Statutes 2012, section 152.02, subdivision 2, is amended to read:
1.6 Subd. 2. Schedule I. (a) Schedule I consists of the substances listed in this
1.7subdivision.
1.8(b) Opiates. Unless specifically excepted or unless listed in another schedule, any of
1.9the following substances, including their analogs, isomers, esters, ethers, salts, and salts
1.10of isomers, esters, and ethers, whenever the existence of the analogs, isomers, esters,
1.11ethers, and salts is possible:
1.12(1) acetylmethadol;
1.13(2) allylprodine;
1.14(3) alphacetylmethadol (except levo-alphacetylmethadol, also known as
1.15levomethadyl acetate);
1.16(4) alphameprodine;
1.17(5) alphamethadol;
1.18(6) alpha-methylfentanyl benzethidine;
1.19(7) betacetylmethadol;
1.20(8) betameprodine;
1.21(9) betamethadol;
1.22(10) betaprodine;
1.23(11) clonitazene;
1.24(12) dextromoramide;
2.1(13) diampromide;
2.2(14) diethyliambutene;
2.3(15) difenoxin;
2.4(16) dimenoxadol;
2.5(17) dimepheptanol;
2.6(18) dimethyliambutene;
2.7(19) dioxaphetyl butyrate;
2.8(20) dipipanone;
2.9(21) ethylmethylthiambutene;
2.10(22) etonitazene;
2.11(23) etoxeridine;
2.12(24) furethidine;
2.13(25) hydroxypethidine;
2.14(26) ketobemidone;
2.15(27) levomoramide;
2.16(28) levophenacylmorphan;
2.17(29) 3-methylfentanyl;
2.18(30) acetyl-alpha-methylfentanyl;
2.19(31) alpha-methylthiofentanyl;
2.20(32) benzylfentanyl beta-hydroxyfentanyl;
2.21(33) beta-hydroxy-3-methylfentanyl;
2.22(34) 3-methylthiofentanyl;
2.23(35) thenylfentanyl;
2.24(36) thiofentanyl;
2.25(37) para-fluorofentanyl;
2.26(38) morpheridine;
2.27(39) 1-methyl-4-phenyl-4-propionoxypiperidine;
2.28(40) noracymethadol;
2.29(41) norlevorphanol;
2.30(42) normethadone;
2.31(43) norpipanone;
2.32(44) 1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine (PEPAP);
2.33(45) phenadoxone;
2.34(46) phenampromide;
2.35(47) phenomorphan;
2.36(48) phenoperidine;
3.1(49) piritramide;
3.2(50) proheptazine;
3.3(51) properidine;
3.4(52) propiram;
3.5(53) racemoramide;
3.6(54) tilidine;
3.7(55) trimeperidine.
3.8(c) Opium derivatives. Any of the following substances, their analogs, salts, isomers,
3.9and salts of isomers, unless specifically excepted or unless listed in another schedule,
3.10whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
3.11(1) acetorphine;
3.12(2) acetyldihydrocodeine;
3.13(3) benzylmorphine;
3.14(4) codeine methylbromide;
3.15(5) codeine-n-oxide;
3.16(6) cyprenorphine;
3.17(7) desomorphine;
3.18(8) dihydromorphine;
3.19(9) drotebanol;
3.20(10) etorphine;
3.21(11) heroin;
3.22(12) hydromorphinol;
3.23(13) methyldesorphine;
3.24(14) methyldihydromorphine;
3.25(15) morphine methylbromide;
3.26(16) morphine methylsulfonate;
3.27(17) morphine-n-oxide;
3.28(18) myrophine;
3.29(19) nicocodeine;
3.30(20) nicomorphine;
3.31(21) normorphine;
3.32(22) pholcodine;
3.33(23) thebacon.
3.34(d) Hallucinogens. Any material, compound, mixture or preparation which contains
3.35any quantity of the following substances, their analogs, salts, isomers (whether optical,
3.36positional, or geometric), and salts of isomers, unless specifically excepted or unless listed
4.1in another schedule, whenever the existence of the analogs, salts, isomers, and salts of
4.2isomers is possible:
4.3(1) methylenedioxy amphetamine;
4.4(2) methylenedioxymethamphetamine;
4.5(3) methylenedioxy-N-ethylamphetamine (MDEA);
4.6(4) n-hydroxy-methylenedioxyamphetamine;
4.7(5) 4-bromo-2,5-dimethoxyamphetamine (DOB);
4.8(6) 2,5-dimethoxyamphetamine (2,5-DMA);
4.9(7) 4-methoxyamphetamine;
4.10(8) 5-methoxy-3, 4-methylenedioxy amphetamine;
4.11(9) alpha-ethyltryptamine;
4.12(10) bufotenine;
4.13(11) diethyltryptamine;
4.14(12) dimethyltryptamine;
4.15(13) 3,4,5-trimethoxy amphetamine;
4.16(14) 4-methyl-2, 5-dimethoxyamphetamine (DOM);
4.17(15) ibogaine;
4.18(16) lysergic acid diethylamide (LSD);
4.19(17) mescaline;
4.20(18) parahexyl;
4.21(19) N-ethyl-3-piperidyl benzilate;
4.22(20) N-methyl-3-piperidyl benzilate;
4.23(21) psilocybin;
4.24(22) psilocyn;
4.25(23) tenocyclidine (TPCP or TCP);
4.26(24) N-ethyl-1-phenyl-cyclohexylamine (PCE);
4.27(25) 1-(1-phenylcyclohexyl) pyrrolidine (PCPy);
4.28(26) 1-[1-(2-thienyl)cyclohexyl]-pyrrolidine (TCPy);
4.29(27) 4-chloro-2,5-dimethoxyamphetamine (DOC);
4.30(28) 4-ethyl-2,5-dimethoxyamphetamine (DOET);
4.31(29) 4-iodo-2,5-dimethoxyamphetamine (DOI);
4.32(30) 4-bromo-2,5-dimethoxyphenethylamine (2C-B);
4.33(31) 4-chloro-2,5-dimethoxyphenethylamine (2C-C);
4.34(32) 4-methyl-2,5-dimethoxyphenethylamine (2-CD);
4.35(33) 4-ethyl-2,5-dimethoxyphenethylamine (2C-E);
4.36(34) 4-iodo-2,5-dimethoxyphenethylamine (2C-I);
5.1(35) 4-propyl-2,5-dimethoxyphenethylamine (2C-P);
5.2(36) 4-isopropylthio-2,5-dimethoxyphenethylamine (2C-T-4);
5.3(37) 4-propylthio-2,5-dimethoxyphenethylamine (2C-T-7);
5.4(38) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-yl)ethanamine
5.5(2-CB-FLY);
5.6(39) bromo-benzodifuranyl-isopropylamine (Bromo-DragonFLY);
5.7(40) alpha-methyltryptamine (AMT);
5.8(41) N,N-diisopropyltryptamine (DiPT);
5.9(42) 4-acetoxy-N,N-dimethyltryptamine (4-AcO-DMT);
5.10(43) 4-acetoxy-N,N-diethyltryptamine (4-AcO-DET);
5.11(44) 4-hydroxy-N-methyl-N-propyltryptamine (4-HO-MPT);
5.12(45) 4-hydroxy-N,N-dipropyltryptamine (4-HO-DPT);
5.13(46) 4-hydroxy-N,N-diallyltryptamine (4-HO-DALT);
5.14(47) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
5.15(48) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT);
5.16(49) 5-methoxy-α-methyltryptamine (5-MeO-AMT);
5.17(50) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
5.18(51) 5-methylthio-N,N-dimethyltryptamine (5-MeS-DMT);
5.19(52) 5-methoxy-N-methyl-N-propyltryptamine (5-MeO-MiPT);
5.20(53) 5-methoxy-α-ethyltryptamine (5-MeO-AET);
5.21(54) 5-methoxy-N,N-dipropyltryptamine (5-MeO-DPT);
5.22(55) 5-methoxy-N,N-diethyltryptamine (5-MeO-DET);
5.23(56) 5-methoxy-N,N-diallytryptamine (5-MeO-DALT);
5.24(57) methoxetamine (MXE);
5.25(58) 5-iodo-2-aminoindane (5-IAI);
5.26(59) 5,6-methylenedioxy-2-aminoindane (MDAI)
5.27(60) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
5.28(25I-NBOMe).
5.29(e) Peyote. All parts of the plant presently classified botanically as Lophophora
5.30williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part
5.31of the plant, and every compound, manufacture, salts, derivative, mixture, or preparation
5.32of the plant, its seeds or extracts. The listing of peyote as a controlled substance in
5.33Schedule I does not apply to the nondrug use of peyote in bona fide religious ceremonies
5.34of the American Indian Church, and members of the American Indian Church are exempt
5.35from registration. Any person who manufactures peyote for or distributes peyote to the
6.1American Indian Church, however, is required to obtain federal registration annually and
6.2to comply with all other requirements of law.
6.3(f) Central nervous system depressants. Unless specifically excepted or unless listed
6.4in another schedule, any material compound, mixture, or preparation which contains any
6.5quantity of the following substances, their analogs, salts, isomers, and salts of isomers
6.6whenever the existence of the analogs, salts, isomers, and salts of isomers is possible:
6.7(1) mecloqualone;
6.8(2) methaqualone;
6.9(3) gamma-hydroxybutyric acid (GHB), including its esters and ethers;
6.10(4) flunitrazepam.
6.11(g) Stimulants. Unless specifically excepted or unless listed in another schedule, any
6.12material compound, mixture, or preparation which contains any quantity of the following
6.13substances, their analogs, salts, isomers, and salts of isomers whenever the existence of
6.14the analogs, salts, isomers, and salts of isomers is possible:
6.15 (1) aminorex;
6.16(2) cathinone;
6.17(3) fenethylline;
6.18 (4) methcathinone;
6.19(5) methylaminorex;
6.20(6) N,N-dimethylamphetamine;
6.21(7) N-benzylpiperazine (BZP);
6.22(8) methylmethcathinone (mephedrone);
6.23(9) 3,4-methylenedioxy-N-methylcathinone (methylone);
6.24(10) methoxymethcathinone (methedrone);
6.25(11) methylenedioxypyrovalerone (MDPV);
6.26(12) fluoromethcathinone;
6.27(13) methylethcathinone (MEC);
6.28(14) 1-benzofuran-6-ylpropan-2-amine (6-APB);
6.29(15) dimethylmethcathinone (DMMC);
6.30(16) fluoroamphetamine;
6.31(17) fluoromethamphetamine;
6.32(18) α-methylaminobutyrophenone (MABP or buphedrone);
6.33(19) β-keto-N-methylbenzodioxolylpropylamine (bk-MBDB or butylone);
6.34(20) 2-(methylamino)-1-(4-methylphenyl)butan-1-one (4-MEMABP or BZ-6378);
6.35(21) naphthylpyrovalerone (naphyrone); and
7.1(22) any other substance, except bupropion or compounds listed under a different
7.2schedule, that is structurally derived from 2-aminopropan-1-one by substitution at the
7.31-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the
7.4compound is further modified in any of the following ways:
7.5(i) by substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy,
7.6haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring
7.7system by one or more other univalent substituents;
7.8(ii) by substitution at the 3-position with an acyclic alkyl substituent;
7.9(iii) by substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or
7.10methoxybenzyl groups; or
7.11(iv) by inclusion of the 2-amino nitrogen atom in a cyclic structure.
7.12(h) Marijuana, tetrahydrocannabinols, and synthetic cannabinoids. Unless
7.13specifically excepted or unless listed in another schedule, any natural or synthetic material,
7.14compound, mixture, or preparation that contains any quantity of the following substances,
7.15their analogs, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers,
7.16whenever the existence of the isomers, esters, ethers, or salts is possible:
7.17(1) marijuana;
7.18(2) tetrahydrocannabinols naturally contained in a plant of the genus Cannabis,
7.19synthetic equivalents of the substances contained in the cannabis plant or in the
7.20resinous extractives of the plant, or synthetic substances with similar chemical structure
7.21and pharmacological activity to those substances contained in the plant or resinous
7.22extract, including, but not limited to, 1 cis or trans tetrahydrocannabinol, 6 cis or trans
7.23tetrahydrocannabinol, and 3,4 cis or trans tetrahydrocannabinol;
7.24(3) synthetic cannabinoids, including the following substances:
7.25(i) Naphthoylindoles, which are any compounds containing a 3-(1-napthoyl)indole
7.26structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
7.27alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
7.282-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any
7.29extent and whether or not substituted in the naphthyl ring to any extent. Examples of
7.30naphthoylindoles include, but are not limited to:
7.31(A) 1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM-678);
7.32(B) 1-Butul-3-(1-naphthoyl)indole (JWH-073);
7.33(C) 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081);
7.34(D) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
7.35(E) 1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015);
7.36(F) 1-Hexyl-3-(1-naphthoyl)indole (JWH-019);
8.1(G) 1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122);
8.2(H) 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210);
8.3(I) 1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398);
8.4(J) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM-2201).
8.5(ii) Napthylmethylindoles, which are any compounds containing a
8.61H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom
8.7of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8.81-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further
8.9substituted in the indole ring to any extent and whether or not substituted in the naphthyl
8.10ring to any extent. Examples of naphthylmethylindoles include, but are not limited to:
8.11(A) 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane (JWH-175);
8.12(B) 1-Pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methan (JWH-184).
8.13(iii) Naphthoylpyrroles, which are any compounds containing a
8.143-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the
8.15pyrrole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8.161-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
8.17further substituted in the pyrrole ring to any extent, whether or not substituted in the
8.18naphthyl ring to any extent. Examples of naphthoylpyrroles include, but are not limited to,
8.19(5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone (JWH-307).
8.20(iv) Naphthylmethylindenes, which are any compounds containing a
8.21naphthylideneindene structure with substitution at the 3-position of the indene
8.22ring by an allkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
8.231-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further
8.24substituted in the indene ring to any extent, whether or not substituted in the naphthyl
8.25ring to any extent. Examples of naphthylemethylindenes include, but are not limited to,
8.26E-1-[1-(1-naphthalenylmethylene)-1H-inden-3-yl]pentane (JWH-176).
8.27(v) Phenylacetylindoles, which are any compounds containing a 3-phenylacetylindole
8.28structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
8.29alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
8.302-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
8.31any extent, whether or not substituted in the phenyl ring to any extent. Examples of
8.32phenylacetylindoles include, but are not limited to:
8.33(A) 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (RCS-8);
8.34(B) 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250);
8.35(C) 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251);
8.36(D) 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203).
9.1(vi) Cyclohexylphenols, which are compounds containing a
9.22-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position
9.3of the phenolic ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9.41-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not
9.5substituted in the cyclohexyl ring to any extent. Examples of cyclohexylphenols include,
9.6but are not limited to:
9.7(A) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP 47,497);
9.8(B) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol
9.9(Cannabicyclohexanol or CP 47,497 C8 homologue);
9.10(C) 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]
9.11-phenol (CP 55,940).
9.12(vii) Benzoylindoles, which are any compounds containing a 3-(benzoyl)indole
9.13structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl,
9.14alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
9.152-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to
9.16any extent and whether or not substituted in the phenyl ring to any extent. Examples of
9.17benzoylindoles include, but are not limited to:
9.18(A) 1-Pentyl-3-(4-methoxybenzoyl)indole (RCS-4);
9.19(B) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694);
9.20(C) (4-methoxyphenyl-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone
9.21(WIN 48,098 or Pravadoline).
9.22(viii) Others specifically named:
9.23(A) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
9.24-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (HU-210);
9.25(B) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)
9.26-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Dexanabinol or HU-211);
9.27(C) 2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]
9.28-1,4-benzoxazin-6-yl-1-naphthalenylmethanone (WIN 55,212-2)
9.29(D) (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144);
9.30(E) (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone
9.31(XLR-11);
9.32(F) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide
9.33(AKB-48(APINACA));
9.34(G) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide
9.35(5-Fluoro-AKB-48);
9.36(H) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid (PB-22); and
10.1(I) 8-quinolinyl ester-1-(5-fluoropentyl)-1H-indole-3-carboxylic acid (5-Fluoro
10.2PB-22).
10.3(i) A controlled substance analog, to the extent that it is implicitly or explicitly
10.4intended for human consumption.
